Elysium Health, a dietary supplement company founded by biologist Leonard Guarente, released its first results about the effect of a supplement product called Basis that the company markets. Basis consists of Nicotinamide Riboside and Pterostilbene. The clinical trial was designed to evaluate the safety and efficacy and in its press release Elysium stated that it met the primary and secondary endpoints. While scant on details the company included the main findings and trial outline.
The study was placebo-controlled, randomized, and double-blinded. Its the first study with a larger amount of participants over a longer duration in humans. The 120 healthy participants, ages 60-80, either received the recommended dose (250 mg NR and 50 mg pterostilbene), double the recommended dose or a placebo daily for the eight-week trial. The following outcomes were observed:
– “no serious adverse events and confirmed that BASIS™ is safe for daily use as determined by standard safety measures”
– In participants taking 250 mg NR and 50 mg pterostilbene “NAD+ levels increased from baseline in whole blood by an average of 40% at four weeks and maintained that increase for the duration of the trial”
– In participants taking 500 mg NR and 100 mg pterostilbene “NAD+ levels increase approximately 90% at four weeks, and a significantly higher level of NAD+ (compared to the recommended dose of BASIS™) was maintained for the duration of the trial”
These finding add further confirmation that an increase NAD+ levels in the blood can be achieved safely and sustainable in againg humans with Nicotinamide Riboside. Pterosilbene is unlikely to be the cause and added for other health benefits e.g. protection against internal and external stress. No other details of the study were revealed. In separate comments Leonard Guarente stated that the trial will continue another 2 years in order to evaluate health benefits.
Interestingly in the same press release the company announced that it has raised $20 million in Series B financing. Considering that Basis is its only product so far, one may speculate that the investors may have gotten a sneak peak of the early health impacts observed in the trials and are trying to position them-self to capture market share before those become known to a wider audience.
You can find the press release here.